Elevated serum biotinidase activity in hepatic glycogen storage disorders–A convenient biomarker by Paesold-Burda, P et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2007
Elevated serum biotinidase activity in hepatic glycogen storage disorders–A
convenient biomarker
Paesold-Burda, P; Baumgartner, M R; Santer, R; Bosshard, N U; Steinmann, B
Abstract: Summary: An elevated serum biotinidase activity in patients with glycogen storage disease
(GSD) type Ia has been reported previously. The aim of this work was to investigate the specificity of
the phenomenon and thus we expanded the study to other types of hepatic GSDs. Serum biotinidase
activity was measured in a total of 68 GSD patients and was compared with that of healthy controls (8.7
±10; range 7.0-10.6mU/ml; n=6). We found an increased biotinidase activity in patients with GSD Ia
(17.7 ±3.9; range: 11.4-24.8; n=21), GSD I non-a (20.9 ±5.6; range 14.6-26.0; n=4), GSD III (12.5 ±-3.6;
range 7.8-19.1; n=3), GSD VI (15.4 ±-2.0; range 14.1-17.7; n=) and GSD IX (14.0 ±-3.8; range: 7.5-21.6;
n=22). The sensitivity of this test was 100% for patients with GSD Ia, GSD I non-a and GSD VI, 62% for
GSD III, and 77% for GSD IX, indicating reduced sensitivity for GSD III and GSD IX, respectively. In
addition, we found elevated biotinidase activity in all sera from 5 patients with Fanconi-Bickel Syndrome
(15.3 ±-3.7; range 11.0-19.4). Taken together, we propose serum biotinidase as a diagnostic biomarker
for hepatic glycogen storage disorders
DOI: https://doi.org/10.1007/s10545-007-0734-4
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-155727
Journal Article
Published Version
Originally published at:
Paesold-Burda, P; Baumgartner, M R; Santer, R; Bosshard, N U; Steinmann, B (2007). Elevated serum
biotinidase activity in hepatic glycogen storage disorders–A convenient biomarker. Journal of Inherited
Metabolic Disease, 30(6):896-902.
DOI: https://doi.org/10.1007/s10545-007-0734-4
ORIGINAL ARTICLE
Elevated serum biotinidase activity in hepatic glycogen
storage disorders–A convenient biomarker
P. Paesold-Burda & M. R. Baumgartner & R. Santer &
N. U. Bosshard & B. Steinmann
Received: 17 July 2007 /Submitted in revised form: 13 September 2007 /Accepted: 17 September 2007 /
Published online: 12 November 2007
# SSIEM and Springer 2007
Summary An elevated serum biotinidase activity in
patients with glycogen storage disease (GSD) type Ia
has been reported previously. The aim of this work was
to investigate the specificity of the phenomenon and
thus we expanded the study to other types of hepatic
GSDs. Serum biotinidase activity was measured in a
total of 68 GSD patients and was compared with that of
healthy controls (8.7 T 1.0; range 7.0–10.6 mU/ml;
n = 26). We found an increased biotinidase activity in
patients with GSD Ia (17.7 T 3.9; range: 11.4–24.8;
n = 21), GSD I non-a (20.9 T5.6; range 14.6–26.0;
n = 4), GSD III (12.5 T3.6; range 7.8–19.1; n = 13),
GSD VI (15.4 T 2.0; range 14.1–17.7; n = 3) and GSD
IX (14.0 T3.8; range: 7.5–21.6; n = 22). The sensitivity of
this test was 100% for patients with GSD Ia, GSD I non-
a and GSD VI, 62% for GSD III, and 77% for GSD IX,
indicating reduced sensitivity for GSD III and GSD IX,
respectively. In addition, we found elevated biotinidase
activity in all sera from 5 patients with Fanconi–Bickel
Syndrome (15.3 T3.7; range 11.0–19.4). Taken together,
we propose serum biotinidase as a diagnostic biomarker
for hepatic glycogen storage disorders.
Abbreviations
BTD biotinidase
FBS Fanconi–Bickel syndrome
GSD glycogen storage disease
LSD lysosmal storage disorder
Introduction
Several studies have shown that serum biotinidase is
markedly elevated in patients with GSD Ia (OMIM
232200; Burlina et al 1996; Hug et al 1994; Saltik et al
2000; Wolf et al 2003). Biotinidase catalyses the
hydrolysis of biocytin to biotin and is responsible for
recycling of endogenous biotin (Hymes and Wolf
1996). The enzyme is synthesized mainly by the liver
and then secreted into the blood (Grier et al 1990).
Biotinidase is not directly related to glycogen metab-
olism and, to date, the cause of increased activity in
GSD type Ia patients has remained unclear. While
previous reports suggested that sensitivity in GSD Ia
patients is high, there has been limited information on
the specificity of these findings. In this study, we
evaluated serum biotinidase activity in a significant
number of patients with enzymatically and/or molecu-
lar genetically proven GSDs including GSD I non-a
(OMIM 232220), GSD III (OMIM 232400), GSD VI
(OMIM 232700) and GSD IX (OMIM 306000), as well
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as patients with Fanconi–Bickel syndrome (FBS),
which is characterized by the failure to transfer glucose
across plasma membranes due to congenital deficiency
of the glucose transporter-2 (OMIM 227810).
Patients and methods
Patients
All patients had a biochemically proven GSD. In most
cases elevated glycogen concentration in the liver was
demonstrated. They were assigned to GSD types I a, I
non-a, III, VI and IX and to FBS according to typical
results of enzymatic and/or molecular genetic studies
(see Tables 2 and 3).
Serum biotinidase activity
Whole blood samples were collected and centrifuged and
the resulting sera were frozen at j20-C until analysis.
Serum biotinidase activity was determined by a
colorimetric assay using biotinyl-p-aminobenzoate as
substrate (Wolf et al 1983). The mean biotinidase activity
in serum from healthy individuals was determined to be
8.7T1.0 mU/ml (range 7.0–10.6; n = 26) and was age-
independent. The inter-assay coefficient of variation for
the activity in a control serum was 7.4% (n = 10).
Quantitative determination of liver glycogen
Liver glycogen was analysed using anthron reagent
(Seifter et al 1950).
Determination of liver enzyme activities
Glucose-6-phosphatase was measured by colorimetric
assessment of inorganic phosphate released from glu-
cose 6-phosphate (Hers 1964). To determine amylo-1,
6-glucosidase activity, 14C-labelled glucose was incor-
porated into glycogen by the in vitro reverse activity,
followed by precipitation and measurement of radio-
labelled glycogen (Van Hoof 1967). Total phosphory-
lase activity was determined in the presence of adenosine
monophosphate by colorimetric measurement of inor-
ganic phosphate released from glucose-l-phosphate
(Hers 1964). Phosphorylase b-kinase activity was mea-
sured as described using exogenous phosphorylase b
from rabbit muscle (Lederer et al 1975).
Mutation analysis
Molecular genetic analysis of affected genes (G6PC,
G6PT1, AGL, PYGL, PHKA2, GLUT2 [SLC2A2])
was performed by sequencing PCR products containing
exons and adjacent intronic segments of these genes
and comparison with the known reference sequences. In
general, these PCR products were generated by specific
sense and antisense primers from genomic DNA
extracted from lymphocytes. Initially, sequencing was
performed using the Thermo-Sequenase cycle sequenc-
ing kit (Amersham/Buchler, Wenden, Germany) with
0.0
5.0
10.0
15.0
20.0
25.0
30.0
n = 21
n = 4
n = 13
n = 3 n = 22
n = 5
n = 9n = 26
L
S
D
F
B
S
G
S
D
 V
I
G
S
D
 IX
G
S
D
 II
I
G
S
D
 I 
n
o
n
-a
G
S
D
 Ia
co
n
tr
o
l
B
io
ti
n
id
as
e
A
ct
iv
it
y 
(m
U
/m
l)
Fig. 1 Summary of biotinidase activities from controls, patients
with hepatic GSD and LSD patients. Means and SD are indi-
cated. Lysosomal storage disorders include Niemann–Pick A
(n = 2), Niemann–Pick C (n = 2), and Gaucher disease (n = 5). The
dashed lines represent the range in controls (7.0–10.6 mU/ml).
FBS, Fanconi–Bickel syndrome; GSD, glycogen storage disorders;
LSD, lysosomal storage disorders
Disorder n Biotinidase activity (mU/ml) Sensitivity (%)
Mean T SD Range
Control 26 8.7 T 1.0 7.0–10.6
GSD Ia 21 17.7 T 3.9 11.4–24.8 100
GSD I non-a 4 20.9 T 5.6 14.6–26.0 100
GSD III 13 12.5 T 3.6 7.8–19.1 62
GSD VI 3 15.4 T 2.0 14.1–17.7 100
GSD IX 22 14.0 T 3.8 7.5–21.6 77
Fanconi–Bickel syndrome 5 15.3 T 3.7 11.0–19.4 100
Table 1 Serum biotinidase
activity in controls and
patients with hepatic
storage disorders
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Table 2 Biotinidase activity in hepatic glycogen storage diseases (GSD) and Fanconi–Bickel syndrome (FBS)
Disorder Patient Biotinidase activity
(mU/ml)
Glycogen
(g/100 g liver)
Enzyme Gene locus
Control mean = 8.7
(range 7.0–10.6; n = 26)
Control mean = 4.6
(range 2.4–6.4; n = 12)
GSD Ia Glc-6-Pase (U/g), liver G6PC
Control: mean = 6.3
(range: 3.4–9.6; n = 17)
1 14.3 10.8 0 c.326C > T/c.272G > C
2 15.8, 12.5 (1 y)a 8.8 0.1 c.326C > T/c.1118C > T
3 19.9 8.7 0 c.326C > T/c.1118C > T
4 20.3 9.5 0.5 c.407G > A/c.675A > G
5 16.0 5.6 0 c.641G > C/c.588G > A
6 24.8, 15.1 (2 y)a 11.6 0.3 c.579G > A (homoz.)
7 18.2 6.6 0.1 c.192A > T/c.326C > T
8 23.2 7.9 0.0 c.326C > T/c.158delC
9 21.8 16.5 0.2 c.326C > T/c.272G > C
10 20.1, 15.1 (2 y)a 10.8 0.0 c.588G > A/c.962C > T
11 18.0 11.3 0.4 c.326C > T/n.i.
12 15.2 n.d. n.d. c.326C > T/c.1118C > T
13 21.6 n.d. n.d. c.326C > T/c.G641 > C
14 14.6 5.0 0.02 c.326C > T/n.i.
15 11.8 11.7 0.5
16 11.4 7.9 0.5
17 13.5 16.4 0.02
18 19.9 8.4 0.4
19 22.3 9.8 0.0
20 14.6 10.2 0.3
21 13.6 7.2 0.3
GSD I non-a G6PT1
1 25.2, 24.3 (3 y)a 8.4 c.1211delCT (homoz.)
2 17.6, 21.8 (4 y)a 15.2 c.250T > A (homoz.)
3 26.0 6.3 c.1211delCT/c.250T > A
4 14.6 n.d. c.1211delCT/c.1348G > A
GSD III Amylo-1,6-glucosidase,
liver (U/g)
AGL
Control mean = 214
(range 157–280; n = 16)
1 15.4 14.0 1.6 c.987C > T/long range del.
2 14.7, 16.1 (2 y)a 17.6 13.0 [c.4459C > T/IVS6 + 3a > g]
(homoz.)
3 15.2 9.7 0.2 c.3980G > A (homoz.)
4 15.4, 15.7 (8 y)a 16.9 1.2 c.1992-3insCG (homoz.)
5 13.8 8.5 0.0 c.3980G > A (homoz.)
6 11.9 13.8 0.0
Amylo-1,6-glucosidase,
Ec (U/g Hb)
Control mean = 2.3
(range 0.9–4.2; n = 17)
7 19.1 n.d. 0.1 c.2497C > T (homoz.)
8 13.6 n.d. 0.6 c.1589C > G/c.2590C > T
GSD VI Phosphorylase (U/g), liver
Control mean = 22.3
(range 11.3–31.3; n = 16)
1 14.1 26.8 5.3
2 17.7 7.4 6.1
3 14.4 9.1 3.9
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33P-labelled terminators, which was later changed to
an automated non-radiographic method using the
BigDye 3.1 chemistry and an ABI Prism 3700 DNA
sequencer (Applied Biosystems, Foster City, CA,
USA). Likewise, the biotinidase gene (BTD) was
analysed in three patients with GSD III and IX,
respectively, and in five individuals with enzymatically
proven biotinidase deficiency.
Results and discussion
Elevated serum biotinidase activity
Based on published data on elevated serum biotinidase
activity in GSD Ia patients, we speculated that
biotinidase might also be elevated in additional GSD
types. As in other inborn errors of metabolism, this
GSD IX Phosphorylase b-kinase,
liver (U/g)
PHKA2
Control mean = 83.5
(range 55.5–112.8; n = 7)
1 17.2, 16.3 (7 y)a 13.9 5.5
2 21.6 14.3 22.8
3 14.5 8.8 28.9
4 16.4 8.7 16.4
5 13.3, 16.6 (1 y)a,
14.5 (7 y)a
11.3 0.0
Phosphorylase b-kinase,
Ec (U/g Hb)
Control mean = 10.2
(range 6.3–12.4; n = 9)
6 16.9 8.9 19.2 c.557G > A
(hemiz.)
7 16.4 n.d. 0.1 c.2747G > T
(hemiz.)
8 10.9 12.4 2.8
9 16.3 n.d. 0.7
10 16.8 n.d. 0.6
11 18.3 n.d. 0.4
12 12.7 n.d. 0.7
Phosphorylase b-kinase,
liver/*Ec
13 14.7 7.4 6.1/*2.7 c.740C > G
(hemizyg.)
14 14.7 17.3 24.9/*1.4
15 19.8 11.0 6.8/*0.4
16 18.0 11.0 6.9/*1.3
17 16.1 9.9 40.0/*8.0
Fanconi–Bickel
Syndrome
GLUT2
1 11.0 n.d. M350 fs370X/R365X
2 11.9 n.d. L368 fs391X (homoz.)
3 16.8 n.d. c.884A > G (homoz.)
4 19.4 n.d. V45 fs74X (homoz.)
5 17.4 n.d. V45 fs74X (homoz.)
n.d. = not determined; n.i. = not identified.
Ec, erythrocytes; Glc-6-Pase, glucose-6-phosphatase; Hb, hemoglobin.
a Biotinidase activity obtained after the first measurement (years).
Table 2 Continued
Disorder Patient Biotinidase activity
(mU/ml)
Glycogen
(g/100 g liver)
Enzyme Gene locus
Control mean = 8.7
(range 7.0–10.6; n = 26)
Control mean = 4.6
(range 2.4–6.4; n = 12)
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phenotype is probably not a reflection of the disease
per se, but rather a consequence of a specific metabolic
derangement. To test this, we measured biotinidase in
sera from GSD patients with other defects of enzyme or
transport proteins involved in the glycogenolytic path-
way. To validate our data, GSD type Ia patients were
also included. The results are summarized in Fig. 1 and
Tables 1 and 2. All subgroups of hepatic glycogen
storage diseases showed a marked increase of serum
biotinidase activity. On average, the increase ranged
from 1.5-fold (GSD type III) up to 2.4-fold (GSD type
I non-a). Interestingly, we also found about 1.8-fold
elevated serum biotinidase activity in five patients with
Fanconi–Bickel syndrome.
Sensitivity
Using mean +2SD as the cut-off value, sensitivity of
the biotinidase test was 100% for patients with GSD
Ia, GSD I non-a and GSD VI. For GSD I non-a (n = 4)
and GSD VI (n = 3) patients, however, more sera will
need to be analysed to confirm these findings.
The sensitivity for GSD type III and IX was 62%
and 77%, respectively. This implies that we identified
patients with biotinidase activities within the normal
range (Table 2). Defects at these enzymatic steps
might cause milder metabolic consequences that are
not sufficient to induce the mechanisms eventually
resulting in elevated biotinidase activity. In this
Table 3 GSD III and GSD IX patients with normal biotinidase activity
Disorder Patient Biotinidase activity
(mU/ml)
Glycogen
(g/100 g liver)
Enzyme Gene locus BTD gene
Control mean = 8.7
(range: 7.0–10.6;
n = 26)
Control mean = 4.6
(range: 2.4–6.4;
n = 12)
GSD III Amylo-1,6-glucosidase,
liver (U/g)
AGL
Control mean = 214
(range 157–280; n = 16)
1 7.8, 9.3 (1 y)a 5.7 0.8 c.2929C > T/c.4221delA WT/WT
2 9.5 14.0 49.0 n.d. n.d.
Amylo-1,6-glucosidase,
Ec (U/g Hb)
Control mean = 2.3
(range 0.9–4.2; n = 17)
3 8.0 0.0 c.1020delA (homoz.) WT/WT
4 8.2 0.03 c.IVS21 + 1G > A/
c.3216-7delGA
n.d.
5 9.6 0.2 n.d. n.d.
GSD IX Phosphorylase b-kinase,
liver (U/g)
PHKA2
Control mean = 83.5
(range 55.5–112.8; n = 7)
1 10.3 13.4 30.5 c.557G > A
(hemiz.)
n.d.
Phosphorylase b-kinase,
Ec (U/g Hb)
Control mean = 10.2
(range 6.3–12.4; n = 9)
2 9.7 n.d. 0.0 c.265dupC/
c454C > T
WT/WT
3 8.1, 10.7 (1 y)a n.d. 0.5 c.1643-62del20
(hemiz.)
n.d.
4 7.5 n.d. 0.6 n.d. n.d.
5 9.4 n.d. 0.5 n.d. n.d.
n.d. = not determined.
Ec, erythrocytes; Hb, hemoglobin; WT, wild-type.
a Biotinidase acitivity obtained after the first measurement (years).
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context, however, it is interesting that we found no
correlation between the residual activities of the
glycogenolytic enzymes and biotinidase activity in vitro
(see Tables 2 and 3). Taken together, these findings
indicate that biotinidase is a less sensitive biomarker
for GSD III and GSD IX.
In order to exclude genetic causes of a restricted
increase of biotinidase activity in individuals with GSD
types III and IX (for example, heterozygosity for a
mutation within the biotinidase gene), the BTD locus
coding for biotinidase was analysed in three of the
patients (Table 3, GSD III, patients 1 and 3; GSD IX,
patient 2). It can be calculated from current screening
programmes that carrier frequency for biotinidase
deficiency in the general population is about one in
70 (Nennstiel-Ratzel et al 2004). However, while all
mutated alleles could be identified in five children with
biotinidase deficiency upon sequence analysis (data
not shown), we have not detected any mutations in the
BTD loci of the three GSD patients. Certainly, the
number of patients tested was small, transcriptional
products were not determined, and the patients_
parents were not investigated for intermediate enzyme
activities. Thus, an additional, independent genetic
cause of inappropriate low biotinidase activity in a
fraction of patients with GSD III and IX cannot
ultimately be excluded.
Individual biochemical features
In Table 2 we summarize the individual biochemical
features of the GSD and FBS patients from our study.
Depending on the data available, liver glycogen
content, residual enzyme activities and/or the affected
gene loci are given. Serum biotinidase activity was
independent of the glycogen content in liver. In
addition, upon repeated measurements in a subset of
patients, we observed no correlation between biotini-
dase activity, age and/or dietary control.
We identified one case with a Ffalse-positive bio-
tinidase test_, i.e., an elevated activity of 14.1 mU/ml in
a patient with cystic fibrosis (OMIM 602421) who
had massive hepatic steatosis. One of the Ffalse-
negative biotinidase tests_, namely normal serum
biotinidase activity (9.6 mU/ml), was observed in a
GSD type III patient with massive liver cirrhosis
(Table 3, patient 5). Restricted biotinidase increase in
this patient was most probably the result of liver
biosynthesis failure. It has been reported previously
that serum biotinidase activity is significantly lower in
children with impaired hepatocellular function
(Pabuccuoglu et al 2002), implying that it is important
to rule out chronic liver parenchymal damage before
applying the biotinidase test in a patient with pre-
sumed GSD.
Biotinidase activity in contrast patients
In order to test whether accumulation of other meta-
bolic intermediates in liver can trigger upregulation of
biotinidase activity, we measured biotinidase in sera
from patients affected by lysosomal storage disorders
(LSDs), including Gaucher disease (OMIM 230800)
and Niemann–Pick disease type A (OMIM 257200) and
type C (OMIM 257220). These disorders are character-
ized by deficient degradation of sphingolipids. In our
patient group, they led to hepatosplenomegaly and
mildly elevated transaminases but no chronic paren-
chymal destruction or cirrhosis. Serum biotinidase
activity was normal in all these patients (Fig. 1) which
argues against a non-specific phenomenon.
Table 4 The effect of freeze-thawing on serum biotinidase
activity
Samples n Freeze-thaw cycles
1 2 3
Control 6 100% 97% 92%
GSD Ia 2 100% 94% 90%
Biotinidase activity was measured at the designated freeze-thaw
cycles. The measurements were done in triplicates. The relative
percentages of biotinidase activities are given. The first freeze-
thaw cycle (1) represents the standard procedure (see
BMethods^) and is defined as 100%.
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Fig. 2 Influence of blood sample storage on biotinidase activity.
Samples from one healthy control were stored at room
temperature as whole blood (-Í-), serum (-0-), heparin blood(-r-), and plasma (--). Biotinidase activity was determined at
days 0, 1, 2 and 3. The horizontal lines represent the range in
sera of controls (7.0–10.6 mU/ml). The measurements were done
in triplicates and mean values are shown
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Blood sample handling and processing
We also assessed the effects of blood sample handling
and processing on serum biotinidase activity, such as
storage, freeze-thawing and transport delay. No signif-
icant differences in enzyme activity upon storage of
serum samples at j20-C for up to one month were
observed (data not shown). Next, serum aliquots from
healthy controls and two unrelated GSD I patients
underwent three freeze-thaw cycles and the activity
was determined after each cycle (Table 4). The first
freeze-thaw cycle represented 100% activity, according
to our standard procedure (see BMethods^). After
three freeze-thaw cycles the drop in biotinidase
activity was about 10%. To investigate transport delays
on biotinidase activity, blood from one healthy indi-
vidual was stored for different periods at room
temperature as native blood, heparinized blood, serum
or plasma. As shown in Fig. 2, the enzymatic activities
at day 0 were quite variable, with the highest activity
measured in serum (10.5 mU/ml) and lowest in plasma
(7.6 mU/ml). Over time, decrease in biotinidase
activity in all samples was about 20%. These results
suggest that biotinidase activities in plasma and serum
samples, isolated at different time points, are not
directly comparable. This fact, together with the less
stringent sensitivity, might explain the normal biotini-
dase activities for GSD type III and IX patients
reported elsewhere (Burlina et al 1996).
Our data show that hepatic glycogen storage
diseases caused by deficiencies of enzymes involved
in glycogen degradation lead to elevated biotinidase
activity in blood. Even though this phenomenon can
be used as a diagnostic tool, we can only speculate
about the mechanism. A key function of biotinidase is
to cleave biotin from biocytin, preserving the pool of
biotin for use as a co-factor for biotin-dependent
enzymes (Hymes and Wolf 1996). We therefore
assume that metabolic pathways in these patients
induce changes in such a way, that the demand for
biotin as enzymatic co-factor is rigorously increased.
In summary, our study revealed significantly elevat-
ed biotinidase activities in sera from patients with
GSD Ia and I non-a, GSD III, VI and IX and FBS.
Thus, given that blood samples are processed properly,
serum biotinidase serves as a simple, non-invasive tool
to narrow down the differential diagnosis of hepato-
megaly prior to specific enzymatic studies and/or
mutation analysis.
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